{"filing":{"accession_number":"0001906324-26-000032","cik":"0001906324","ticker":"QDEL","company_name":"QuidelOrtho Corp","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"qdel-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000032/qdel-20260806.htm"},"events":[{"id":26007,"run_id":23618,"accession_number":"0001906324-26-000032","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"QuidelOrtho issued a press release on August 6, 2026 announcing second quarter 2026 financial results (total revenue $631 million, GAAP net loss $93 million, adjusted diluted EPS $0.13) and materially revised full-year 2026 guidance downward—reducing revenue guidance from $2.70-$2.75B to $2.52-$2.60B and adjusted EPS from $1.80-$2.00 to $0.65-$0.90, citing China pricing headwinds and softer respiratory demand. The press release is furnished as Exhibit 99.1 and disclosed under Item 2.02, the standard Item for earnings releases.","company_name":"QuidelOrtho Corp","ticker":"QDEL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26982,"accession_number":"0001906324-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"QuidelOrtho issued a press release on August 6, 2026 announcing second quarter 2026 financial results (total revenue $631 million, GAAP net loss $93 million, adjusted diluted EPS $0.13) and materially revised full-year 2026 guidance downward—reducing revenue guidance from $2.70-$2.75B to $2.52-$2.60B and adjusted EPS from $1.80-$2.00 to $0.65-$0.90, citing China pricing headwinds and softer respiratory demand. The press release is furnished as Exhibit 99.1 and disclosed under Item 2.02, the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:54:56.289995+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26982,"accession_number":"0001906324-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"QuidelOrtho issued a press release on August 6, 2026 announcing second quarter 2026 financial results (total revenue $631 million, GAAP net loss $93 million, adjusted diluted EPS $0.13) and materially revised full-year 2026 guidance downward—reducing revenue guidance from $2.70-$2.75B to $2.52-$2.60B and adjusted EPS from $1.80-$2.00 to $0.65-$0.90, citing China pricing headwinds and softer respiratory demand. The press release is furnished as Exhibit 99.1 and disclosed under Item 2.02, the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:54:56.289995+00:00","company_name":"QuidelOrtho Corp","ticker":"QDEL","filing_date":"2026-08-06"}]}